Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2
about
Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS responseEnteric bacterial toxins: mechanisms of action and linkage to intestinal secretion.Evaluation of colicins for inhibitory activity against diarrheagenic Escherichia coli strains, including serotype O157:H7Toxicity of Shiga toxin 1 in the central nervous system of rabbitsPathogenesis of Shiga toxin-associated hemolytic uremic syndrome.Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: Microbiological aspects.The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice.Shiga toxin 1 induces on lipopolysaccharide-treated astrocytes the release of tumor necrosis factor-alpha that alter brain-like endothelium integrity.Serum antibodies to Escherichia coli serotype O157:H7 in patients with hemolytic uremic syndromeShiga Toxin 2a-Induced Endothelial Injury in Hemolytic Uremic Syndrome: A Metabolomic Analysis.Phage-typing of Vero-cytotoxin (VT) producing Escherichia coli O157 isolated in the United Kingdom.Properties of Vero cytotoxin-producing Escherichia coli of human and animal origin belonging to serotypes other than O157:H7Antibodies to Escherichia coli O157 in patients with haemorrhagic colitis and haemolytic uraemic syndromeHuman mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injuryCharacterization of verocytotoxin-producing Escherichia coli O157 isolates from patients with haemolytic uraemic syndrome in Western Europe.A prospective study of exposure to verotoxin-producing Escherichia coli among Canadian children with haemolytic uraemic syndrome. The CPKDRC co-investigators.Structure and function of plasmid pColD157 of enterohemorrhagic Escherichia coli O157 and its distribution among strains from patients with diarrhea and hemolytic-uremic syndrome.Non-O157:H7 Stx2-producing Escherichia coli strains associated with sporadic cases of hemolytic-uremic syndrome in adults.Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humansHemolytic uremic syndrome: Events of the past decade.Comparison of the relative toxicities of Shiga-like toxins type I and type II for miceThe MAP kinase-activated protein kinase 2 (MK2) contributes to the Shiga toxin-induced inflammatory responseSyntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice.Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cellsEffects of Shiga toxin 2 on lethality, fetuses, delivery, and puerperal behavior in pregnant mice.Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia.Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infectionMouse models of Escherichia coli O157:H7 infection and shiga toxin injectionDirect evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice.Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccinesA new immunoglobulin-binding protein, EibG, is responsible for the chain-like adhesion phenotype of locus of enterocyte effacement-negative, shiga toxin-producing Escherichia coli.Expression and purification of Shiga-like toxin II B subunits.Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethalityEscherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood.An in vitro combined antibiotic-antibody treatment eliminates toxicity from Shiga toxin-producing Escherichia coliExtended phage-typing scheme for Escherichia coli O157:H7Infection by verocytotoxin-producing Escherichia coliShiga Toxin (Stx) Type 1a Reduces the Oral Toxicity of Stx Type 2a
P2860
Q24647531-5D9ACCA3-F0C7-47D0-A96E-DEC2FAB97038Q30449794-1173E1FD-987C-4A6B-A587-05EA40940129Q30452883-B9448E6A-2242-4296-9EFB-27252B1207A3Q30453693-37E2DEE3-BCF7-4E07-89B3-30302978C26AQ33338331-B3349E2A-307D-4187-A84B-131F595FFAC3Q33363266-6B75F4E7-B35D-44F2-9883-09044CBFCCEDQ33397728-3D57FD06-B491-436D-961D-8E0ADBD45812Q33399096-FAD8FC3B-CAFB-4AA2-8454-EDB0AFBA1A5DQ33400603-A3503614-E8E3-410E-827E-E5FDDB4CA83EQ33426514-8DCA71B6-6E76-4819-AB96-4EF61AFA3385Q33427669-DE90C97D-621C-4660-81B9-06C7BB73468AQ33428956-55470DE7-80E7-4B3C-A346-DB121BD37302Q33428960-AA39F164-FA2C-4ACF-9E91-819171FD2FECQ33429198-F9AF4A3E-E620-4BC8-BFEF-614C1F27E625Q33433630-3551F0BF-1080-40BF-A85C-D44025D89881Q33488924-A54DCBBF-61DA-485C-8519-FCE47F76DB19Q33494314-C1026A95-0EF4-4EF4-8799-56EEA6C17FA0Q33501374-C5543FE2-D937-4A8B-AB1B-D1548775835FQ33502702-83052FAE-15B5-4EF3-B50A-567AAE3AB715Q33505189-32082FBC-32D0-40AE-B140-094D209A30B9Q33559388-5368AAAD-A951-43B8-A951-A31169F67FC9Q33605233-0BA3C243-24EB-4E5B-BFC6-165DBFF33D09Q33808280-6527E375-B430-46BB-B651-1BA1B1C37C15Q34002606-376B0834-5D47-4AD0-BD65-6E379DBAA614Q34002866-AC97EC29-BEE7-4B11-AEF1-DF05AC98132DQ34004015-F037A9A7-0684-46DE-92DC-C6C3ACACE570Q34033376-6F8D54DE-37E2-467C-BA20-93CE2E2A67D7Q34394719-CCFF2C92-C928-4E63-8745-AC22224D2846Q34497115-8CD2116F-A6DA-4C70-B51A-386AAE97CB51Q34534278-04A15E5B-5601-4B3C-9551-79F3CB6CC7F8Q34545082-99C16EE0-FA29-417B-8C22-BE0A0EE97019Q35073895-90A47882-534C-47F7-826F-1498565B0B82Q35381150-1D01D539-EB18-4353-BDDD-6C2D687337E1Q35551789-7019EF5F-13A0-4A35-9B9D-F3AEC25BD713Q35773392-E538255A-5CEC-4224-8A47-D2A987C8523EQ35816742-0F37B64F-E829-41EC-89DA-CC107D4AAA29Q35961023-7D66454D-2242-4FCA-AEF6-AD2F0953860BQ36505072-4EFA457E-1838-4A78-A054-DF842E53ED76Q36634680-30D06C8A-13E1-493D-B077-4F57F1F89A14Q36705833-92A5B5AE-B358-450F-BD69-0B9BB74B6C24
P2860
Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Properties of strains of Esche ...... of Vero cytotoxins VT1 and VT2
@ast
Properties of strains of Esche ...... of Vero cytotoxins VT1 and VT2
@en
type
label
Properties of strains of Esche ...... of Vero cytotoxins VT1 and VT2
@ast
Properties of strains of Esche ...... of Vero cytotoxins VT1 and VT2
@en
prefLabel
Properties of strains of Esche ...... of Vero cytotoxins VT1 and VT2
@ast
Properties of strains of Esche ...... of Vero cytotoxins VT1 and VT2
@en
P2093
P2860
P1476
Properties of strains of Esche ...... of Vero cytotoxins VT1 and VT2
@en
P2093
P2860
P304
P356
10.1017/S0950268800066462
P577
1987-12-01T00:00:00Z